Polpharma Strengthens Its Position in Central and Eastern Europe – Biofarm, the Leader of the Romanian Market, Joins the Group

Polpharma Group has completed the acquisition of the Romanian pharmaceutical company Biofarm. The transaction is a clear step in the execution of the Group’s growth strategy and strengthens its position in Central and Eastern Europe. With Biofarm joining the Group, Polpharma is expanding the scale of its operations, reinforcing its presence in key regional markets, and creating new opportunities to improve patients’ access to trusted medicines across the region and beyond.

Biofarm’s acquisition reflects the Group’s ambition to grow internationally while staying true to its core priorities: responsibility towards patients and contributing to the modern and sustainable development of healthcare systems.

The integration of the Romanian company increases Polpharma’s scale, strengthens its presence in key Central and Eastern European markets, and enables better use of manufacturing, operational, and commercial capabilities developed across the region.

Poland sets the direction for the Group’s development

International expansion is a natural stage of Polpharma’s growth and a direct consequence of its strategy to build a strong position in Central and Eastern Europe. As a privately owned company, Polpharma combines long-term thinking with an entrepreneurial mindset: speed in decision-making, accountability, and close cooperation across markets and teams. Expanding into new markets as part of an integrated pharmaceutical platform in Europe, enables the Group to increase its scale, broaden its capabilities, and strengthen an organization managed from Poland while drawing on know-how and experience gained across multiple markets.

“Poland remains the place from which we define the strategic direction of our Group and pursue our ambitious international growth plans. The acquisition of Biofarm confirms our long-term commitment to building a strong, multiregional pharmaceutical organization. We are a privately owned company with an entrepreneurial gene: we act responsibly, move with speed, and believe in cooperation. This is how we want to grow — always with patients’ needs at the center and with a tangible contribution to improving access to medicines and strengthening pharmaceutical security across Central and Eastern Europe,” says Sebastian Szymanek, CEO of Polpharma Group.

Benefits for patients and healthcare systems

Combining the strengths of both organizations creates greater opportunities to develop and provide patients with access to a broader portfolio of trusted products. Biofarm’s strong position in Romania and Polpharma’s regional footprint create a platform to support the continued availability of Biofarm products in Romania, while also opening potential for their presence in additional markets. At the same time, the transaction creates an opportunity to further strengthen the presence of Polpharma’s existing products in the Romanian market.

All these opportunities will be pursued with care for patients and in line with the responsibility that both companies bring to healthcare. By integrating competencies, experience, and resources, Polpharma Group will be able to develop its operations in the region more effectively, increase operational efficiency, and support pharmaceutical security through the continued strengthening of local manufacturing and distribution capabilities.

Biofarm – a strong partner in the Romanian market

Biofarm is one of the most recognized pharmaceutical manufacturers in Romania. The company has operated continuously since 1921, owns two manufacturing facilities, and exports its products to countries across Europe and Asia. Its portfolio includes more than 200 products spanning dozens of therapeutic areas.

“Joining Polpharma Group opens up new opportunities for Biofarm’s future development. By combining the experience of our local team, deep market knowledge, and the strength of the Group, we will be able to develop our product portfolio even more effectively, explore opportunities for Biofarm products in other markets, and create greater value for patients and business partners,” says Tamás Uri, General Manager, CEE Region at Polpharma Group.

Integration based on continuity and cooperation

In the coming phases, the Group will focus on leveraging the synergies resulting from the combination of competencies, product portfolios, and the experience of both organizations. Biofarm’s integration creates a strong foundation for further strengthening Polpharma Group’s position in Central and Eastern Europe, supporting the development of Biofarm products beyond their current markets, and reinforcing the presence of Polpharma’s portfolio in Romania. This will be done with continuity, cooperation, and responsibility towards patients as the guiding principles.

About Polpharma

Polpharma is the leader of the Polish pharmaceutical market and one of the leading pharmaceutical manufacturers in Central and Eastern Europe. Founded in 1935, Zakłady Farmaceutyczne Polpharma S.A. has evolved into a multiregional pharmaceutical platform engaged in the development, manufacturing, and commercialization of prescription medicines, over-the-counter products, active pharmaceutical ingredients, and innovative solutions for patients and business partners worldwide. Approximately 400 million packs of medicines leave the company’s production facilities each year. Polpharma’s mission is “Helping people live healthy lives in a healthy world.” The company continuously invests in the development of products and technologies, collaborates with scientists, and supports the advancement of scientific communities through the activities of the Polpharma Scientific Foundation. It operates in accordance with the principles of responsible business, paying close attention to social and environmental aspects while maintaining the highest ethical standards.

Media contact:

Grażyna Stachowska
M: +48 885 610 273
E: grazyna.stachowska@polpharma.com